The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study.

The concomitant use of angiotensin-converting enzyme inhibitors (ACEIs) and aspirin is recommended for any diabetic patient with microalbuminuria or macroalbuminuria because these drugs result in renal and cardiovascular benefits (1,2). However, a putative pharmacological interaction between these drugs is plausible, through their opposite effects on vasodilator prostaglandins (3). Therefore, the aim of this study was to analyze the possible interference of intermediate-dose aspirin (300 mg/day) on urinary albumin excretion (UAE) reduction properties of enalapril in microalbuminuric type 2 diabetic patients. In this randomized, crossover, double-blind, placebo-controlled …